1,275
Participants
Start Date
June 30, 2016
Primary Completion Date
June 13, 2019
Study Completion Date
September 2, 2020
SOF/LDV (sofosbuvir/ledipasvir)
Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)
Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)
EBR/GZR (elbasvir/grazoprevir)
Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks
Ribavirin
200 mg pills (1-3 pills, 1-2 times per day)
Mt. Sinai Beth Israel, New York
New York Langone Medical Center, New York
Weill Cornell Medical College, New York
Columbia University Medical Center, New York
Mountain View Medical Center, Valatie
University of Pennsylvania, Philadelphia
Georgetown University, Washington D.C.
Howard University, Washington D.C.
John Hopkins University, Lutherville
Bon Secours St. Mary 's Hospital of Richmond (Liver Institute of Virginia), Richmond
Virginia Commonwealth University, Richmond
University of North Carolina at Chapel Hill, Chapel Hill
Duke University Medical Center, Durham
Internal Medicine Associates of Wellstar Atlanta Medical Center, Atlanta
University of Florida, Jacksonville, Jacksonville
Orlando Immunology Center, Orlando
University of Miami/Schiff Center for Liver Diseases, Miami
GI Associates & Endoscopy Center, Flowood
University of Cincinnati, Cincinnati
Indiana University Medical Center, Indianapolis
University of Michigan, Ann Arbor
University of Minnesota, Minneapolis
Northwestern University, Chicago
Northwestern University, Chicago
Saint Louis University, St Louis
University of Nebraska Medical Ctr, Omaha
Liver Wellness Center, Little Rock
Research Specialist of Texas, Houston
Southwest CARE Center, Santa Fe
UCSD Medical Center, San Diego
UCSF/Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco
Univ of California, San Francisco, San Francisco
Stanford University, Palo Alto
Virginia Mason Medical Center, Seattle
University of Washington, Seattle
Yale University Digestive Diseases, New Haven
University of Florida, Gainesville
Massachusetts General Hospital, Boston
Collaborators (1)
Patient-Centered Outcomes Research Institute
OTHER
Merck Sharp & Dohme LLC
INDUSTRY
AbbVie
INDUSTRY
University of Florida
OTHER